The treatment of chronic depression, part 2

A double-blind, randomized trial of sertraline and imipramine

M. B. Keller, A. J. Gelenberg, R. M A Hirschfeld

Research output: Contribution to journalArticle

Abstract

Background: Chronic depression appears to be a common, frequently disabling illness that is often inadequately treated. Unlike for episodic depressions with shorter illness duration, neither acute nor long-term treatment approaches for chronic depression have been well studied. Method: 635 outpatients at 12 sites who met DSM-III.R criteria for chronic major depression or double depression, were randomly assigned to 12 weeks of double-blind treatment with either sertraline (in daily doses of 50-200 mg) or imipramine..(in daily doses of 50-300 mg). Efficacy and safety were assessed either weekly or every 2 weeks during the 12 weeks of acute treatment. Results: Despite high rates of chronicity (mean duration of major depression = 8.9±9.1 years; mean duration of dysthymia = 23±13 years) and high rates of comorbidity, 52% of patients achieved a satisfactory therapeutic response to sertraline or imipramine (by a conservative, intent-to-treat analysis). Approximately 21% of the patients who had achieved a therapeutic response at week 12 had not done so at week 8, confirming the longer time to response in depressions with high chronicity. Patients treated with sertraline reported significantly fewer adverse events and were significantly less likely to discontinue treatment due to side effects than imipramine-treated patients (6.3% vs. 12.0%). Conclusion: These results indicate that patients suffering from depression with high chronicity can achieve a good therapeutic response to acute treatment with either sertraline or imipramine, although sertraline is better tolerated.

Original languageEnglish (US)
Pages (from-to)27-28
Number of pages2
JournalPrimary Care Companion to the Journal of Clinical Psychiatry
Volume1
Issue number1
StatePublished - 1999

Fingerprint

Sertraline
Imipramine
Therapeutics
Diagnostic and Statistical Manual of Mental Disorders
Comorbidity
Outpatients
Safety

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

The treatment of chronic depression, part 2 : A double-blind, randomized trial of sertraline and imipramine. / Keller, M. B.; Gelenberg, A. J.; Hirschfeld, R. M A.

In: Primary Care Companion to the Journal of Clinical Psychiatry, Vol. 1, No. 1, 1999, p. 27-28.

Research output: Contribution to journalArticle

@article{32281b6e85a0494a9e1f3bf281c239a4,
title = "The treatment of chronic depression, part 2: A double-blind, randomized trial of sertraline and imipramine",
abstract = "Background: Chronic depression appears to be a common, frequently disabling illness that is often inadequately treated. Unlike for episodic depressions with shorter illness duration, neither acute nor long-term treatment approaches for chronic depression have been well studied. Method: 635 outpatients at 12 sites who met DSM-III.R criteria for chronic major depression or double depression, were randomly assigned to 12 weeks of double-blind treatment with either sertraline (in daily doses of 50-200 mg) or imipramine..(in daily doses of 50-300 mg). Efficacy and safety were assessed either weekly or every 2 weeks during the 12 weeks of acute treatment. Results: Despite high rates of chronicity (mean duration of major depression = 8.9±9.1 years; mean duration of dysthymia = 23±13 years) and high rates of comorbidity, 52{\%} of patients achieved a satisfactory therapeutic response to sertraline or imipramine (by a conservative, intent-to-treat analysis). Approximately 21{\%} of the patients who had achieved a therapeutic response at week 12 had not done so at week 8, confirming the longer time to response in depressions with high chronicity. Patients treated with sertraline reported significantly fewer adverse events and were significantly less likely to discontinue treatment due to side effects than imipramine-treated patients (6.3{\%} vs. 12.0{\%}). Conclusion: These results indicate that patients suffering from depression with high chronicity can achieve a good therapeutic response to acute treatment with either sertraline or imipramine, although sertraline is better tolerated.",
author = "Keller, {M. B.} and Gelenberg, {A. J.} and Hirschfeld, {R. M A}",
year = "1999",
language = "English (US)",
volume = "1",
pages = "27--28",
journal = "The primary care companion for CNS disorders",
issn = "1523-5998",
publisher = "Physicians Postgraduate Press Inc.",
number = "1",

}

TY - JOUR

T1 - The treatment of chronic depression, part 2

T2 - A double-blind, randomized trial of sertraline and imipramine

AU - Keller, M. B.

AU - Gelenberg, A. J.

AU - Hirschfeld, R. M A

PY - 1999

Y1 - 1999

N2 - Background: Chronic depression appears to be a common, frequently disabling illness that is often inadequately treated. Unlike for episodic depressions with shorter illness duration, neither acute nor long-term treatment approaches for chronic depression have been well studied. Method: 635 outpatients at 12 sites who met DSM-III.R criteria for chronic major depression or double depression, were randomly assigned to 12 weeks of double-blind treatment with either sertraline (in daily doses of 50-200 mg) or imipramine..(in daily doses of 50-300 mg). Efficacy and safety were assessed either weekly or every 2 weeks during the 12 weeks of acute treatment. Results: Despite high rates of chronicity (mean duration of major depression = 8.9±9.1 years; mean duration of dysthymia = 23±13 years) and high rates of comorbidity, 52% of patients achieved a satisfactory therapeutic response to sertraline or imipramine (by a conservative, intent-to-treat analysis). Approximately 21% of the patients who had achieved a therapeutic response at week 12 had not done so at week 8, confirming the longer time to response in depressions with high chronicity. Patients treated with sertraline reported significantly fewer adverse events and were significantly less likely to discontinue treatment due to side effects than imipramine-treated patients (6.3% vs. 12.0%). Conclusion: These results indicate that patients suffering from depression with high chronicity can achieve a good therapeutic response to acute treatment with either sertraline or imipramine, although sertraline is better tolerated.

AB - Background: Chronic depression appears to be a common, frequently disabling illness that is often inadequately treated. Unlike for episodic depressions with shorter illness duration, neither acute nor long-term treatment approaches for chronic depression have been well studied. Method: 635 outpatients at 12 sites who met DSM-III.R criteria for chronic major depression or double depression, were randomly assigned to 12 weeks of double-blind treatment with either sertraline (in daily doses of 50-200 mg) or imipramine..(in daily doses of 50-300 mg). Efficacy and safety were assessed either weekly or every 2 weeks during the 12 weeks of acute treatment. Results: Despite high rates of chronicity (mean duration of major depression = 8.9±9.1 years; mean duration of dysthymia = 23±13 years) and high rates of comorbidity, 52% of patients achieved a satisfactory therapeutic response to sertraline or imipramine (by a conservative, intent-to-treat analysis). Approximately 21% of the patients who had achieved a therapeutic response at week 12 had not done so at week 8, confirming the longer time to response in depressions with high chronicity. Patients treated with sertraline reported significantly fewer adverse events and were significantly less likely to discontinue treatment due to side effects than imipramine-treated patients (6.3% vs. 12.0%). Conclusion: These results indicate that patients suffering from depression with high chronicity can achieve a good therapeutic response to acute treatment with either sertraline or imipramine, although sertraline is better tolerated.

UR - http://www.scopus.com/inward/record.url?scp=53149139373&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53149139373&partnerID=8YFLogxK

M3 - Article

VL - 1

SP - 27

EP - 28

JO - The primary care companion for CNS disorders

JF - The primary care companion for CNS disorders

SN - 1523-5998

IS - 1

ER -